Claudine Isaacs, MD, and community oncologists weigh ASCENT-03 and ASCENT-04 data, crossover, and toxicity management with sacituzumab govitecan in TNBC.
|Podcasts|August 22, 2021
OncView™ Podcast: NCCN Guideline Updates in HR+ Breast Cancer: Focus on Extended Adjuvant Therapy
Author(s)Matthew Fowler, Lee Schwartzberg, MD, FACP
This special episode of “Oncology Peer Review On-The-Go” features Lee Schwartzberg, MD, FACP discussing treatment patterns in HR-positive breast cancer with.
Advertisement
As part of its OncView™ video series, CancerNetwork® spoke with Lee Schwartzberg, MD, FACP, of the West Cancer Center and Research Institute in Germantown, Tennessee, about updates to the National Comprehensive Cancer Network (NCCN) guidelines regarding hormone receptor (HR)–positive breast cancer.
In the video series, Lee Schwartzberg, MD, FACP, discussed the following:
Extended Adjuvant Therapy for HR+ Breast Cancer Molecular Biomarkers for HR+ Breast Cancer Role of Genomic Testing in HR Positive Breast Cancer Appropriateness for Genomic Testing in HR+ Breast Cancer Integration of Genomic Testing into NCCN Guidelines Current Recommendations for Genomic Testing in HR+ Breast Cancer Treatment Limitations in HR+ Breast Cancer
To watch more videos in CancerNetwork®’s OncView™ series, visit
Don’t forget to subscribe to the “Oncology Peer Review On-The-Go” podcast on Apple Podcasts, Spotify or anywhere podcasts are available.
Advertisement
Related to this article
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
Mark Burkard, MD, PhD, discussed genomic gaps, extreme survivors of metastatic breast cancer, and how minimal residual disease testing may refine care.
Hope S. Rugo, MD, discussed KEYNOTE-B49 data showing pembrolizumab plus chemotherapy improved PFS in PD-L1-positive HR+/HER2- breast cancer.
Jan Kitajewski, PhD, discusses how an ancestry-linked blood type may influence triple-negative breast cancer outcomes and clinical trial eligibility.
Black women die from breast cancer at rates 40% higher than white women — and are still missing from the trials that could help. Dr. Coral Omene on why.
The European Commission approved adjuvant T-DXd for HER2-positive early breast cancer with residual invasive disease based on DESTINY-Breast05 data.
Jan Kitajewski, PhD, explains how Notch inhibitors may sustain specialized tumor blood vessels that deliver immune cells and boost immuno-oncology.
Advertisement
Advertisement
Trending on CancerNetwork
1
Setting Up an HDR Brachytherapy Program Amid a National Decline
2
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
3
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
4
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
5